{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:58:11Z","timestamp":1781632691075,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"DOI":"10.7759\/cureus.110973","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:27:49Z","timestamp":1781630869000},"source":"Crossref","is-referenced-by-count":0,"title":["The Evidence-Practice Gap in Testosterone Therapy for Prostate Cancer: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Mohammed","family":"Aly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer","volume":"368","author":"Resnick MJ","year":"2013","unstructured":"Resnick MJ, Koyama T, Fan KH, et al.. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013, 368:436-45. 10.1056\/NEJMoa1209978","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda MG","year":"2008","unstructured":"Sanda MG, Dunn RL, Michalski J, et al.. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008, 358:1250-61. 10.1056\/NEJMoa074311","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2020.12.003","article-title":"Testosterone therapy after prostate cancer treatment: a review of literature","volume":"9","author":"Natale C","year":"2021","unstructured":"Natale C, Carlos C, Hong J, Khera M, Baum N, Raheem OA. Testosterone therapy after prostate cancer treatment: a review of literature. Sex Med Rev. 2021, 9:393-405. 10.1016\/j.sxmr.2020.12.003","journal-title":"Sex Med Rev"},{"key":"ref4","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins C","year":"1941","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941, 1:293-7.","journal-title":"Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler A","year":"2009","unstructured":"Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009, 55:310-20. 10.1016\/j.eururo.2008.09.024","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-025-01206-3","article-title":"Testosterone replacement therapy following definitive treatment for prostate cancer: a scoping review of safety and efficacy","author":"Gibson J","year":"2025","unstructured":"Gibson J, George M, Grice P, Mohee A, Stasinou T, Pearce I, Modgil V. Testosterone replacement therapy following definitive treatment for prostate cancer: a scoping review of safety and efficacy. Int J Impot Res. 2025, 10.1038\/s41443-025-01206-3","journal-title":"Int J Impot Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16870","article-title":"Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies","volume":"136","author":"Santucci J","year":"2025","unstructured":"Santucci J, Stapleton P, Perera M, et al.. Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies. BJU Int. 2025, 136:788-99. 10.1111\/bju.16870","journal-title":"BJU Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.250086","article-title":"Testosterone replacement therapy in hypogonadal men with a prostate cancer diagnosis: a British Society for Sexual Medicine consensus statement","volume":"44","author":"Edison MA","year":"2026","unstructured":"Edison MA, Kirby M, Hackett GI. Testosterone replacement therapy in hypogonadal men with a prostate cancer diagnosis: a British Society for Sexual Medicine consensus statement. World J Mens Health. 2026, 44:5-22. 10.5534\/wjmh.250086","journal-title":"World J Mens Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.94872","article-title":"Testosterone replacement in prostate carcinoma: a systematic review of an emerging paradigm and therapeutic potential","volume":"17","author":"Robinson J","year":"2025","unstructured":"Robinson J, Banerjee I, Banerjee I. Testosterone replacement in prostate carcinoma: a systematic review of an emerging paradigm and therapeutic potential. Cureus. 2025, 17:e94872. 10.7759\/cureus.94872","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.04.065","article-title":"Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory","volume":"186","author":"Khera M","year":"2011","unstructured":"Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011, 186:1005-11. 10.1016\/j.juro.2011.04.065","journal-title":"J Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2020.61.3.242","article-title":"Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer","volume":"61","author":"Kim JW","year":"2020","unstructured":"Kim JW. Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer. Investig Clin Urol. 2020, 61:242-9. 10.4111\/icu.2020.61.3.242","journal-title":"Investig Clin Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2020.61.4.452","article-title":"Letter to the editor: questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer","volume":"61","author":"Morgentaler A","year":"2020","unstructured":"Morgentaler A, Traish AM. Letter to the editor: questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer. Investig Clin Urol. 2020, 61:452-4. 10.4111\/icu.2020.61.4.452","journal-title":"Investig Clin Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm323","article-title":"Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies","volume":"100","author":"Roddam AW","year":"2008","unstructured":"Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008, 100:170-83. 10.1093\/jnci\/djm323","journal-title":"J Natl Cancer Inst"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.5304","article-title":"Testosterone replacement therapy and risk of favorable and aggressive prostate cancer","volume":"35","author":"Loeb S","year":"2017","unstructured":"Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol. 2017, 35:1430-6. 10.1200\/JCO.2016.69.5304","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Bhasin S, Flevaris P, et al.. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023, 389:107-17. 10.1056\/NEJMoa2215025","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.48692","article-title":"Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial","volume":"6","author":"Bhasin S","year":"2023","unstructured":"Bhasin S, Travison TG, Pencina KM, et al.. Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial. JAMA Netw Open. 2023, 6:e2348692. 10.1001\/jamanetworkopen.2023.48692","journal-title":"JAMA Netw Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-026-01237-4","article-title":"Cardiovascular and prostate cancer risk associated to testosterone replacement therapy - a systematic review and meta-analysis of 41 randomized controlled trials","author":"Garc\u00eda-Becerra CA","year":"2026","unstructured":"Garc\u00eda-Becerra CA, Arias-Gallardo MI, Ju\u00e1rez-Garc\u00eda JE, et al.. Cardiovascular and prostate cancer risk associated to testosterone replacement therapy - a systematic review and meta-analysis of 41 randomized controlled trials. Int J Impot Res. 2026, 10.1038\/s41443-026-01237-4","journal-title":"Int J Impot Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/1008-682X.160270","article-title":"Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results","volume":"18","author":"Kacker R","year":"2016","unstructured":"Kacker R, Hult M, San Francisco IF, Conners WP, Rojas PA, Dewolf WC, Morgentaler A. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016, 18:16-20. 10.4103\/1008-682X.160270","journal-title":"Asian J Androl"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.06.002","article-title":"Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?","volume":"41","author":"Daza J","year":"2023","unstructured":"Daza J, Ahmad A, Shabir U, et al.. Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?. Urol Oncol. 2023, 41:429.e1-7. 10.1016\/j.urolonc.2023.06.002","journal-title":"Urol Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.01.005","article-title":"Oncologic outcomes of testosterone therapy for men on active surveillance for prostate cancer: a population-based analysis","volume":"60","author":"Kaplan-Marans E","year":"2024","unstructured":"Kaplan-Marans E, Zhang TR, Hu JC. Oncologic outcomes of testosterone therapy for men on active surveillance for prostate cancer: a population-based analysis. Eur Urol Open Sci. 2024, 60:36-43. 10.1016\/j.euros.2024.01.005","journal-title":"Eur Urol Open Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/jsxmed\/qdaf003","article-title":"Testosterone replacement therapy in men on active surveillance for prostate cancer","volume":"22","author":"Applewhite J","year":"2025","unstructured":"Applewhite J, McCarter J, Saffati G, et al.. Testosterone replacement therapy in men on active surveillance for prostate cancer. J Sex Med. 2025, 22:432-8. 10.1093\/jsxmed\/qdaf003","journal-title":"J Sex Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2009.01161.x","article-title":"Testosterone replacement therapy following radical prostatectomy","volume":"6","author":"Khera M","year":"2009","unstructured":"Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009, 6:1165-70. 10.1111\/j.1743-6109.2009.01161.x","journal-title":"J Sex Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.02.002","article-title":"Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy","volume":"190","author":"Pastuszak AW","year":"2013","unstructured":"Pastuszak AW, Pearlman AM, Lai WS, et al.. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013, 190:639-44. 10.1016\/j.juro.2013.02.002","journal-title":"J Urol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-0241-3","article-title":"Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease","volume":"23","author":"Sarkar RR","year":"2020","unstructured":"Sarkar RR, Patel SH, Parsons JK, et al.. Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. Prostate Cancer Prostatic Dis. 2020, 23:689-95. 10.1038\/s41391-020-0241-3","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15042","article-title":"Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy","volume":"126","author":"Ahlering TE","year":"2020","unstructured":"Ahlering TE, My Huynh L, Towe M, et al.. Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy. BJU Int. 2020, 126:91-6. 10.1111\/bju.15042","journal-title":"BJU Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004267","article-title":"Testosterone therapy in men after radical prostatectomy for low-intermediate organ-confined prostate cancer","volume":"213","author":"Flores JM","year":"2025","unstructured":"Flores JM, Vertosick EA, Salter CA, et al.. Testosterone therapy in men after radical prostatectomy for low-intermediate organ-confined prostate cancer. J Urol. 2025, 213:27-33. 10.1097\/JU.0000000000004267","journal-title":"J Urol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22438","article-title":"Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy","volume":"109","author":"Sarosdy MF","year":"2007","unstructured":"Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007, 109:536-41. 10.1002\/cncr.22438","journal-title":"Cancer"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.05.084","article-title":"Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer","volume":"194","author":"Pastuszak AW","year":"2015","unstructured":"Pastuszak AW, Khanna A, Badhiwala N, et al.. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol. 2015, 194:1271-6. 10.1016\/j.juro.2015.05.084","journal-title":"J Urol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12668","article-title":"Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer","volume":"114","author":"Balbontin FG","year":"2014","unstructured":"Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int. 2014, 114:125-30. 10.1111\/bju.12668","journal-title":"BJU Int"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall JP","year":"2018","unstructured":"Mulhall JP, Trost LW, Brannigan RE, et al.. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018, 200:423-32. 10.1016\/j.juro.2018.03.115","journal-title":"J Urol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.7252","article-title":"Canadian Urological Association guideline on testosterone deficiency in men: Evidence-based Q&A","volume":"15","author":"Grober ED","year":"2021","unstructured":"Grober ED, Krakowsky Y, Khera M, et al.. Canadian Urological Association guideline on testosterone deficiency in men: Evidence-based Q&A. Can Urol Assoc J. 2021, 15:E234-43. 10.5489\/cuaj.7252","journal-title":"Can Urol Assoc J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.04.010","article-title":"European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie's disease","volume":"88","author":"Salonia A","year":"2025","unstructured":"Salonia A, Capogrosso P, Boeri L, et al.. European Association of Urology guidelines on male sexual and reproductive health: 2025 update on male hypogonadism, erectile dysfunction, premature ejaculation, and Peyronie's disease. Eur Urol. 2025, 88:76-102. 10.1016\/j.eururo.2025.04.010","journal-title":"Eur Urol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/jsxmed\/qdaf181","article-title":"Testosterone therapy and lawsuits against prescribers: a legal case review from 2000 to 2024","volume":"22","author":"Pourabhari Langroudi A","year":"2025","unstructured":"Pourabhari Langroudi A, Basran S, Chen AL, et al.. Testosterone therapy and lawsuits against prescribers: a legal case review from 2000 to 2024. J Sex Med. 2025, 22:1572-8. 10.1093\/jsxmed\/qdaf181","journal-title":"J Sex Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/496269-the-evidence-practice-gap-in-testosterone-therapy-for-prostate-cancer-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:27:50Z","timestamp":1781630870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/496269-the-evidence-practice-gap-in-testosterone-therapy-for-prostate-cancer-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.110973","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}